Combination chemo-radiotherapy for residual, recurrent or inoperable carcinoma of the rectum: E.C.O.G. study (EST 3276)

Irradiation with and without Razoxane in the Treatment of Incompletely Resected or Inoperable Recurrent Rectal Cancer

“…A median survival around 12 months was a common value in the literature until 1994, even for combination chemoradiotherapy with 5-FU-based regimens [4,6,7,11,27,39]. In the present study, the group with radiation therapy alone achieved a median survival which is comparable to the razoxane-treated group of the previous study, the survival in the razoxane arm remained at a similar value as seen earlier.…”

Prognostic factors affecting oncologic outcomes in patients with locally recurrent rectal cancer: impact of patterns of pelvic recurrence on curative resection

“…Radiotherapy alone or in combination with chemotherapy palliates patients with recurrent disease, but long-term survival is not expected. Furthermore, 5-year survival is approximately 5% without surgical intervention [7][8][9], and palliative surgery alone prolongs mean survival to about 11 months [10,11]. In previous literature, radical resection of the locally recurrent tumors and achieving microscopically negative margins can offer the only chance for long-term survival, 12% to 33% of 5-year survival, but a high rate of perioperative morbidity is still a concern [12][13][14][15].…”

Split-Course Radiotherapy: Where Do We Stand?

“…The study by Danjoux et al [27] was excluded because it includes chemotherapy. The study by Spanos et al [116] was excluded because it compared two split-course regimens with different gap durations.…”